medroxyprogesterone acetate has been researched along with Kidney Diseases in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arias-Loza, PA; Blode, H; Elmore, SA; Ertl, G; Fritzemeier, KH; Hegele-Hartung, C; Hu, K; Maronpot, R; Muehlfelder, M; Pelzer, T | 1 |
| Barrett-Connor, E; Bibbins-Domingo, K; Grady, D; Hulley, SB; Lin, F; Shlipak, MG; Vittinghoff, E | 1 |
| Deo, R; Hulley, SB; Lin, F; Shlipak, MG; Tseng, ZH; Vittinghoff, E | 1 |
| Gondo, H; Nakajima, Y; Sato, N; Sato, Y; Uchino, J; Une, Y | 1 |
| Mol, JA; Selman, PJ; van den Ingh, TS; van Garderen, E | 1 |
2 trial(s) available for medroxyprogesterone acetate and Kidney Diseases
| Article | Year |
|---|---|
Kidney dysfunction and sudden cardiac death among women with coronary heart disease.
Topics: Aged; Coronary Disease; Death, Sudden, Cardiac; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Incidence; Kidney Diseases; Medroxyprogesterone Acetate; Middle Aged; Multivariate Analysis; Postmenopause; Predictive Value of Tests; Risk Factors | 2008 |
Chemohormonal therapy of unresectable hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Cisplatin; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Kidney Diseases; Leukopenia; Liver Diseases; Liver Neoplasms; Male; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Staging; Prospective Studies; Remission Induction; Survival Rate; Tamoxifen | 1993 |
3 other study(ies) available for medroxyprogesterone acetate and Kidney Diseases
| Article | Year |
|---|---|
Differential effects of 17beta-estradiol and of synthetic progestins on aldosterone-salt-induced kidney disease.
Topics: Aldosterone; Androstenes; Animals; Blood Pressure; Epithelial Sodium Channels; Estradiol; Female; Hypertrophy; Kidney; Kidney Diseases; Medroxyprogesterone Acetate; Oxidative Stress; Progesterone Congeners; Proliferating Cell Nuclear Antigen; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Cytoplasmic and Nuclear; Sodium Chloride; Spironolactone | 2009 |
Predictors of heart failure among women with coronary disease.
Topics: Aged; Atrial Fibrillation; Black or African American; Bundle-Branch Block; Cohort Studies; Comorbidity; Coronary Disease; Diabetes Mellitus; Estrogens, Conjugated (USP); Follow-Up Studies; Heart Failure; Hormone Replacement Therapy; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Diseases; Medroxyprogesterone Acetate; Middle Aged; Obesity; Postmenopause; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors | 2004 |
Comparison of the histological changes in the dog after treatment with the progestins medroxyprogesterone acetate and proligestone.
Topics: Adrenal Cortex; Animals; Antineoplastic Agents, Hormonal; Atrophy; Chemical and Drug Induced Liver Injury; Contraceptive Agents, Female; Delayed-Action Preparations; Dog Diseases; Dogs; Female; Fibroadenoma; Hysterectomy; Kidney Diseases; Liver Diseases; Mammary Neoplasms, Animal; Medroxyprogesterone Acetate; Ovariectomy; Progesterone; Progesterone Congeners | 1995 |